Skip to main content
Fig. 5 | Stem Cell Research & Therapy

Fig. 5

From: Clinical efficacy and safety of multipotent adult progenitor cells (invimestrocel) for acute respiratory distress syndrome (ARDS) caused by pneumonia: a randomized, open-label, standard therapy–controlled, phase 2 multicenter study (ONE-BRIDGE)

Fig. 5

Patient quality of life in the invimestrocel and standard treatment groups. (a) EQ-5D-5L index score and (b) summary score of each item of EQ-5D-5L at baseline and day 90 after treatment administration. Baseline was defined as ventilator weaning. ARDS acute respiratory distress syndrome, BL baseline, EQ-5D-5L EuroQol 5-Dimension 5-Level

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512